文献速递其他结缔组织病

阿尼鲁单抗治疗30例难治性皮肌炎的真实世界多中心回顾性研究

Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre-multidisciplinary retrospective study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

这项多中心、多学科回顾性研究评估了阿尼鲁单抗在30例经同情用药治疗的难治性皮肌炎患者中的真实世界结局。结果显示,皮肤病变从第1个月起即显著改善,肌功能改善且肌酸激酶(CK)恢复正常,活动性关节炎全部缓解,间质肺病稳定或改善,糖皮质激素剂量显著减少且50%停用,不良事件多为轻度。

要点

  • 皮肤病变从第1个月起显著改善,CDASI-A由23降至6(P<0.001)。
  • MMT-8改善且CK于第1个月恢复正常,活动性关节炎(n=3)全部缓解。
  • 糖皮质激素剂量显著减少(P<0.001)且50%停用,不良事件多为轻度(16.7%)。

核心结论

  • 阿尼鲁单抗在难治性皮肌炎中显示出快速、多系统疗效,具有显著激素节约效应和良好安全性。

研究设计与样本

  • 多中心、多学科回顾性研究,纳入30例经同情用药接受阿尼鲁单抗治疗的难治性皮肌炎患者。
  • 在基线及第1、3、6、12个月采用CDASI-A、MMT-8、关节和肺部评估及糖皮质激素减量评估疾病活动度。

主要发现

  • 治疗指征包括难治性皮肤病变(73.3%)、皮肤-肌肉型(13.4%,含1例肺部进展)及其他表现(13.3%),50%患者未联用免疫抑制治疗。
  • CDASI-A从23(IQR 10.8-30.5)降至6(IQR 3-10),P<0.001,向阳性皮疹和Gottron丘疹较脱发反应更快。
  • MMT-8从142.5(IQR 127-148)改善至146.5(IQR 139-150),P<0.05;CK从332 IU/l(IQR 211.5-893.5)降至146 IU/l(IQR 106.5-481.8)。
  • 活动性关节炎患者(n=3)全部缓解,间质肺病(n=6)经肺功能检查和/或CT评估稳定或改善;糖皮质激素剂量显著减少(P<0.001)且50%停用。
  • 不良事件为轻度(16.7%患者),1例89岁患者死于肺炎;1例因难治性瘙痒需乌帕替尼,1例因疗效丧失停用阿尼鲁单抗。

关键数值与推荐

  • CDASI-A由23(IQR 10.8-30.5)降至6(IQR 3-10),P<0.001。
  • MMT-8由142.5(IQR 127-148)改善至146.5(IQR 139-150),P<0.05。
  • CK由332 IU/l(IQR 211.5-893.5)降至146 IU/l(IQR 106.5-481.8)。
  • 糖皮质激素剂量显著减少(P<0.001),50%患者停用。

临床怎么用

  • 对难治性皮肌炎皮肤及肌肉病变可考虑阿尼鲁单抗,并注意其激素节约效应。
  • 治疗中需监测不良事件,尤其高龄患者感染风险。

局限性

  • 为回顾性研究,样本量30例,部分指标以中位数(IQR)报告,缺乏对照組。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess real-world outcomes of anifrolumab (ANI) in refractory systemic DM. METHODS: This multicentre and multidisciplinary, retrospective study evaluated 30 DM patients receiving ANI through compassionate use. Disease activity was assessed at baseline and months 1, 3, 6 and 12 using Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A), Manual Muscle Testing-8 (MMT-8), joint and pulmonary evaluation and glucocorticoid tapering. Safety included adverse event documentation and treatment discontinuation rates. RESULTS: Treatment indications included refractory cutaneous (73.3%), cutaneous-muscular (13.4%, including one pulmonary progression case) and other manifestations (13.3%). ANI was initiated without concomitant immunosuppressive therapy in 50% of patients. Cutaneous improvement was observed from month 1 (CDASI-A: 23 [IQR 10.8-30.5] to 6 [IQR 3-10]; P < 0.001), with heliotrope rash and Gottron's papules responding faster than alopecia. Muscular function improved (MMT-8: 142.5 [IQR 127-148] to 146.5 [IQR 139-150]; P < 0.05) with creatine kinase (CK) normalization (332 IU/l [IQR 211.5-893.5] to 146 IU/l [IQR 106.5-481.8]) at month 1. All active arthritis patients (n = 3) achieved remission, with no articular flares observed among patients with historical joint involvement. Interstitial lung disease cases (n = 6) demonstrated stabilization or improvement as assessed by pulmonary function tests and/or computed tomography. Glucocorticoid dose significantly reduced (P < 0.001), discontinued in 50%. Adverse events were mild (16.7% patients); one 89-year-old patient died from pneumonia. One patient required upadacitinib for refractory pruritus; one discontinued ANI for efficacy loss. CONCLUSION: ANI showed rapid, multisystem efficacy in refractory DM with significant steroid-sparing effects and a favourable safety profile.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Retuerto-Guerrero M, Moriano Morales C, Pareja-Martínez A, et al. Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre-multidisciplinary retrospective study. Rheumatology (Oxford). 2026. PMID: 41400930. doi:10.1093/rheumatology/keaf662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。